Laura Fisch

Laura Fisch

Auto-generated profile, based on publicly available information

Laura Fisch

BioMed X GmbH, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2022 in Science
Verified
Journal Article
Closed access
DBDjenet Bousbaine
Djenet Bousbaine
LFLaura I. Fisch
Laura I. Fisch
MLMariya London
Mariya London
PBPreksha Bhagchandani
Preksha Bhagchandani
TCTiago B. Rezende de Castro
Tiago B. Rezende de Castro
ABAngelina M. Bilate
Angelina M. Bilate
The microbiome contributes to the development and maturation of the immune system. In response to commensal bacteria, intestinal CD4 + T lymphocytes differentiate into functional subtypes with regulatory or effector functions. The development of small intestine intraepithelial lymphocytes that coexpress CD4 and CD8αα homodimers (CD4IELs) depends on the microbiota. However, the identity of the microbial antigens recognized by CD4 + T cells that can differentiate into CD4IELs remains unknown. We identified β-hexosaminidase, a conserved enzyme across commensals of the Bacteroidetes phylum, as a driver of CD4IEL differentiation. In a mouse model of colitis, β-hexosaminidase–specific lymphocytes protected against intestinal inflammation. Thus, T cells of a single specificity can recognize a variety of abundant commensals and elicit a regulatory immune response at the intestinal mucosa.

2 February 2024 in Science Advances
Verified
Journal Article
Open access
MCMiray Cetin
Miray Cetin
VPVeronica Pinamonti
Veronica Pinamonti
TSTheresa Schmid
Theresa Schmid
TBTamara Boschert
Tamara Boschert
AFAna Mellado Fuentes
Ana Mellado Fuentes
JLJohn M. Lindner
John M. Lindner
Effective, unbiased, high-throughput methods to functionally identify both class II and class I HLA–presented T cell epitopes and their cognate T cell receptors (TCRs) are essential for and prerequisite to diagnostic and therapeutic applications, yet remain underdeveloped. Here, we present T-FINDER [T cell Functional Identification and (Neo)-antigen Discovery of Epitopes and Receptors], a system to rapidly deconvolute CD4 and CD8 TCRs and targets physiologically processed and presented by an individual’s unmanipulated, complete human leukocyte antigen (HLA) haplotype. Combining a highly sensitive TCR signaling reporter with an antigen processing system to overcome previously undescribed limitations to target expression, T-FINDER both robustly identifies unknown peptide:HLA ligands from antigen libraries and rapidly screens and functionally validates the specificity of large TCR libraries against known or predicted targets. To demonstrate its capabilities, we apply the platform to multiple TCR-based applications, including diffuse midline glioma, celiac disease, and rheumatoid arthritis, providing unique biological insights and showcasing T-FINDER’s potency and versatility.

18 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
TSTheresa Schmid
Theresa Schmid
MCMiray Cetin
Miray Cetin
VPVeronica Pinamonti
Veronica Pinamonti
AFAna Mellado Fuentes
Ana Mellado Fuentes
KKKristina Kromer
Kristina Kromer
JLJohn M. Lindner
John M. Lindner
Effective, unbiased, high-throughput methods to functionally identify both class II and class I HLA-presented T cell epitopes and their cognate T cell receptors (TCRs) are essential for and prerequisite to diagnostic and therapeutic applications, yet remain underdeveloped. Addressing this bottleneck, we established T-FINDER (T cell Functional Identification and (Neo)-antigen Discovery of Epitopes and Receptors), a platform that rapidly deconvolutes CD4 and CD8 TCR reactivities to targets physiologically processed and presented by an individual’s unmanipulated, complete HLA haplotype. By using a highly sensitive TCR signaling reporter capable of detecting even low-affinity TCR:ligand interactions, T-FINDER not only robustly identifies unknown peptide:HLA ligands from complex antigen libraries, but also rapidly screens and functionally validates the specificity of complex TCR libraries against known or predicted targets. To demonstrate its pan-HLA presentation capacity, we apply the platform to multiple TCR-based applications, including glioma, celiac disease, and rheumatoid arthritis, providing unique biological insights and showcasing T-FINDER’s potency and versatility.